Step-down estrogen therapy
OwnerThomas W. Leonard, R. Forrest Waldoninventors
Life of this patent
Estimating the term…
Abstract
The present invention includes methods for treating vasomotor symptoms through the administration of estrogenic compounds. The methods presented may include starting estrogen therapy at a high dose, and then lowering the dose once therapy has been shown to be effective.
Claims55
A method of treating vasomotor symptoms comprising:
- administering a first dose of a therapeutic amount of an estrogenic compound to a subject;
- and
- administering a second dose of a therapeutic amount of an estrogenic compound at a later time period to the subject, said second dose comprising a lower dosage of said therapeutic amount of an estrogenic compound than said first dose.
A method of treating menopause comprising:
- administering a first dose of a therapeutic amount of an estrogenic compound to a subject;
- and
- administering a second dose of a therapeutic amount of an estrogenic compound to the subject at a later time period, said second dose comprising a lower dosage of said therapeutic amount of an estrogenic compound than said first dose.
A method of treating hormonal deficiencies in a subject comprising:
- administering a first dose of a therapeutic amount of an estrogenic compound to a subject;
- and
- administering a second dose of a therapeutic amount of an estrogenic compound to the subject at a later time period, said second dose comprising a lower dosage of said therapeutic amount of an estrogenic compound than said first dose.
A method of treating vasomotor symptoms in a subject, said method comprising:
- administering continuously and uninterruptedly for a first predetermined time period a first dose of an estrogenic compound to said subject;
- and
- administering continuously and uninterruptedly for a second predetermined time period a second dose of an estrogenic compound to said subject.
A method for treating a patient afflicted with vasomotor symptoms, comprising administering an estrogenic compound to said patient for at least two cycles of a cyclical dosing schedule, wherein the first cycle comprises a dosing period of 4 to 12 weeks, in which the estrogenic compound is administered daily, at a dose of 0.625 to 1.5 mg/day, followed by a second cycle comprising a dosing period that can last for an indeterminate period of time in which an estrogenic compound is administered daily, at a dose of 0.05 to 0.625 mg/day.
A method for treating a patient afflicted with vasomotor symptoms, comprising administering an estrogenic compound to said patient for at least two cycles of a cyclical dosing schedule, wherein the first cycle comprises a dosing period until such dosing has been shown to be effectively established, in which the estrogenic compound is administered daily, at a dose of 0.625 to 1.5 mg/day, followed by a second cycle comprising a dosing period that can last for an indeterminate period of time in which an estrogenic compound is administered daily, at a dose of 0.05 to 0.625 mg/day.
Dependencies are inferred from the claim text.